EU Antitrust: Raids on Pharma Companies and E.ON Divestments
Client Alert | 1 min read | 11.26.08
EU Commission raids pharma companies days before sector inquiry interim report
The European Commission has confirmed that it conducted antitrust dawn raids at the offices of several pharmaceutical companies in Europe on November 24. The raids come four days before publication of the interim report in the Commission’s pharmaceuticals sector inquiry investigating competition issues in the industry. Press reports have identified both generic and originator companies as targets of the raids.
The Commission has said that the latest raids are not part of the sector inquiry and are not linked to the earlier raids that launched the inquiry on January 15. However, knowledge acquired during the inquiry has, it said, allowed it to “draw conclusions on where Commission action based on competition law could be appropriate and effective”.
The Commission’s press release confirming the raids is available by clicking here: Antitrust: Commission confirms unannounced inspections at pharmaceutical companies
-------------------------------------------------------------------------------------
EU Commission accepts binding divestment commitments from E.ON in the wake of its energy sector inquiry
On November 26 the Commission formally accepted binding commitments from the German energy giant E.ON to divest (i) its transmission system business consisting of an Extra-High-Voltage (380/220 kV) line network and system operations (currently run by E.ON Netz) and (ii) 5000MW of generation capacity. E.ON’s offer to divest comes in the wake of the Commission’s 2006 energy sector inquiry, which identified competition concerns arising from E.ON’s ownership of both the transmission network and generating capacity in Germany, and a subsequent investigation of E.ON for alleged abuse of market dominance . The allegations included (i) withholding output to drive up electricity prices and (ii) granting preferential network access to its own generation business while passing the resulting costs on to consumers.
The Commission’s press release is available by clicking here: Antitrust: Commission opens German electricity market to competition
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
